Cambridge Heart Reports Fourth Quarter 1999 Results.

Business Editors and Health/Medical Writers

BEDFORD, Mass.--(BW HealthWire)--Feb. 16, 2000

Cambridge Heart, Inc. (NASDAQ:CAMH) today reported revenues of $500,861 for the quarter ended December 31, 1999, compared with revenue of $585,401 for the same period in 1998, a decrease of 14%. Net loss for the fourth quarter of 1999 was $2,039,160, or $0.15 per share, compared to a loss of $1,547,899, or $0.14 per share, for the fourth quarter of 1998. Revenue from the sale of Alternans systems and disposable sensors for the quarter ended December 31, 1999 increased 61% from the same period in 1998 accounting for 68% of total revenue for the quarter. Disposable sensor revenues increased to $46,600 for the quarter, an increase of 104% over the prior year and 17% over the prior quarter,

For the twelve month period ended December 31, 1999 and 1998 revenues were $2,135,981 and $2,096,853 respectively, an increase of 2%. Net loss for both December 31, 1999 and 1998 is a loss of $0.61. Cash, cash equivalents, and marketable securities at the end of the year were $9,187,130. Not included in this figure is an additional $2,075,000 in net investment concluded during January.

"Prior to release of our treadmill version of the alternans product in September our sales primarily came from sales of standard stress test systems plus a few Alternans systems sold for research," said Jeffrey M. Arnold, Cambridge Heart Chairman, President, and Chief Executive Officer. "With this introduction, we were able to shift our emphasis to the sale of Alternans systems for clinical use and generating continuing revenues from the clinical use of our proprietary disposable Alternans sensors. As a result, revenue from the sale of standard stress test systems without the alternans option are down, while sales of Alternans systems and disposables are up substantially on a year-to-year basis."

"We are now selling to those clinicians passionate enough about our technology to purchase and use our test despite the lack of a clear track record of reimbursement for it - a tiny fraction of the market," continued Mr. Arnold. "Our challenge for 2000 is to obtain and demonstrate reimbursement from payers across the country; as indicated by our recent success in California, we are making good progress with this and expect to continue to do so."

Approximately 9 million stress tests are performed each year in the U.S. alone. Cambridge Heart's proprietary sensors are designed to separate T-wave alternans from background noise during routine exercise stress testing during the Company's Alternans Test, the only FDA-cleared noninvasive cardiac diagnostic test to identify patients at risk for sudden cardiac death.

About the Cambridge Heart Alternans Test

The Cambridge Heart Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. T-wave alternans is not visible on electrocardiograms used in conjunction with ordinary exercise stress tests. These tiny heartbeat variations - measured at one millionth of a volt - are detected during a typical treadmill or bicycle exercise stress test by proprietary sensors placed on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack. The Company, founded in 1992, is based in Bedford, Massachusetts and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements made in this news release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements including uncertainties concerning market acceptance, reimbursement and other factors that are included in Cambridge Heart's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

                         Cambridge Heart, Inc.
                         Financial Highlights
Statement of Operations
                        Three months ended             Year ended
                             December 31,              December 31,
                          1999         1998         1999        1998
                      (Unaudited) (Unaudited   (Unaudited) (Unaudited)

Revenues               $500,861     $585,401   $2,135,981  $2,096,853
Cost of goods sold      489,353      487,532    2,006,557   1,848,155

                         11,508       97,869      129,424     248,698
Costs and expenses
 Research and
  development           752,907      731,939    2,839,423   3,594,941
 Selling and
  marketing           1,022,317      602,108    3,202,659   2,178,138
 Administrative         395,292      411,867    1,753,840   1,575,158
  Loss from
   operations        (2,159,008)  (1,648,045)  (7,666,498  (7,099,539)
Interest income         119,848      100,146      331,084     562,454
Net Loss            $(2,039,160) $(1,547,899) $(7,335,414 $(6,537,085)
Net loss per
 share -
 basic and
 diluted                 $(0.15)      $(0.14)      $(0.61      $(0.61)
Weighted average
 shares
 outstanding -
 basic
 and diluted         13,795,789   10,897,522   11,933,261  10,748,508


Balance Sheet                               December 31,  December 31,
                                                 1999         1998
Assets
      Cash & Marketable Securities           $9,176,316   $6,490,353
      Accounts receivable, net                  577,156      555,991
      Inventory                                 460,913      426,489
      Other prepaid assets                      140,197      190,667
           Total current assets              10,354,582    7,663,500
      Fixed assets, net                         645,931      647,629
      Other assets                              453,097      403,604

                                            $11,453,610   $8,714,733
Liabilities and stockholders' equity
      Accounts payable and accrued expenses  $1,404,321     $901,791
Stockholders' equity
      Common stock                               13,921       10,906
      Additional paid-in-capital             39,120,605   29,603,435
      Accumulated deficit                   (29,035,801) (21,700,389)
      Deferred compensation                     (49,436)    (101,010)
           Total stockholders' equity        10,049,289    7,812,942

                                            $11,453,610   $8,714,733


The Company intends to file its annual report on Form 10-K with the
Securities and Exchange Commission shortly.

Interested parties are encouraged to review this report.